


# International Journal of Medicine and Pharmaceutical Research

CODEN (USA): IJCPNH | ISSN: 2321-2624 Journal Home Page: www.pharmaresearchlibrary.com/ijmpr



# RESEARCH ARTICLE

Analytical Method Development and Validation for the Simultaneous Estimation of Saxagliptin and Dapagliflozin in Combined Dosage Form by using RP-HPLC

Gampa Vijay Kumar<sup>1</sup>, T.Rajesh<sup>2</sup>, Thirupathi Krishna<sup>3</sup>

#### ABSTRACT

High performance liquid chromatography is at present one of the most sophisticated tool of the analysis. The estimation of Saxagliptin and Dapagliflozin was done by RP-HPLC. The Phosphate buffer was p<sup>H</sup> 3.0 and the mobile phase was optimized with consists of Methanol: Phosphate buffer mixed in the ratio of 70:30 % v/ v. Inertsil C<sub>18</sub> column C18 (4.6 x 150mm, 5μm) or equivalent chemically bonded to porous silica particles was used as stationary phase. The detection was carried out using UV detector at 260 nm. The solutions were chromatographed at a constant flow rate of 0.8 ml/min. the linearity range of Saxagliptin and Dapagliflozin were found to be from 100-500 mg/ml of Saxagliptin and 1-5mg/ml of Dapagliflozin. Linear regression coefficient was not more than 0.999. The values of % RSD are less than 2% indicating accuracy and precision of the method. The percentage recovery varies from 98-102% of Saxagliptin and Dapagliflozin. LOD and LOQ were found to be within limit. The results obtained on the validation parameters met ICH and USP requirements .it inferred the method found to be simple, accurate, precise and linear. The method was found to be having suitable application in routine laboratory analysis with high degree of accuracy and precision.

Keywords: Inertsil C18, Saxagliptin and Dapagliflozin, RP-HPLC

#### ARTICLE INFO

Corresponding Author Thirupathi Krishna

Department of Pharmacy,

KGR Institute of Technology and Management,

Rampally, Kesara, Medchal, Telangana, India.

MS-ID: IJMPR4148



# ARTICLE HISTORY: Received 09 Oct 2019, Accepted 29 Nov 2019, Available Online 10 Feb 2020

Copyright©2020 Thirupathi Krishna et al, Production and hosting by Pharma Research Library. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

Citation: Thirupathi Krishna, et al. Analytical Method Development and Validation for the Simultaneous Estimation of Saxagliptin and Dapagliflozin in Combined Dosage Form by Using RP-HPLC. Int. J. Med. Pharm. Res., 2020, 8(1): 09-13.

## **CONTENTS**

1.	Introduction
2.	Materials and Method
3.	Results and Discussion
4.	Conclusion
5.	References


<sup>&</sup>lt;sup>1</sup>Professor and Head, Dept. of Pharmacy, KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

<sup>&</sup>lt;sup>2</sup>KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

<sup>&</sup>lt;sup>3</sup>KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

#### 1. Introduction

Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol- Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to codevelop the final compound and collaborate on the marketing of the drug.



Saxagliptin

Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (Sresponsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. In clinical trials, dapagliflozin lowered  $HbA_{1c}$  by 0.6 versus placebo percentage points when added to Metformin.

Dapagliflozin

# 2. Materials and Method

HPLC WATERS, software: Empower, 2695 separation module, PDA detector. UV/VIS spectrophotometer LABINDIA, UV  $3000^{+}$ pH meter, weighing machine. Saxagliptin and Dapagliflozin, KH<sub>2</sub>PO<sub>4</sub>, Water and Methanol for HPLC, Acetonitrile for HPLC, Ortho phosphoric Acid.

Table 1: Chromatographic condition

Parameters	Description
Flow rate	1ml min <sup>-1</sup>
Column	kromosil C <sub>18</sub> Column
	(250mm x 4.6mm)5μg.
Mobile Phase	Phosphate buffer: Methanol P <sup>H</sup>
	4.5(20:80 v/v)
	Potassium dihydrogen orthophosphate
Buffer	PH 4.5 adjusted with Orthophosphoric
	acid
Detector	PDA
Column	Ambient
temperature	
Type of	Isocratic
elution	
Wavelength	254 nm
Injection	20µl

volume	
Run time	10min




Fig.no.1. Chromatogram of Trail-6

**Observation:** The separation of two analytical peaks was good. The plate count also above 2000, tailing factor below 2, and the resolution is above 2. The condition is taken as optimized method.

### **Standard Solution Preparation:**

Accurately weigh and transfer 10 mg of Saxagliptin and Dapagliflozin 10mg of working standard into a 10mL& 100ml clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

#### (Stock solution)

Further pipette 3ml& 0.3ml of the above stock solutions into a 10ml volumetric flask and dilute up to the mark with diluent.

## **Sample Solution Preparation:**

Accurately weigh 10 tablets crush in mortor and pestle and transfer equivalent to 10 mg of Saxagliptin and Dapagliflozin (marketed formulation) sample into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

#### (Stock solution)

Further pipette 3 ml of Saxagliptin e and Dapagliflozin of the above stock solution into a 10ml volumetric flask and dilute up to the mark with diluent.

#### **Method Validation Precision:**

Accurately weigh and transfer 25 mg of Saxagliptin and Dapagliflozin working standard into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

# **Intermediate Precision/Ruggedness:**

To evaluate the intermediate precision (also known as Ruggedness) of the method, Precision was performed on different day by using different make column of same dimensions.

**Accuracy:** Accurately weigh and transfer 10 mg of Saxagliptin and Dapagliflozin 10mg of working standard into a 10mL& 100ml clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

**Linearity:** Accurately weigh 10 tablets crush in mortor and pestle and transfer equivalent to 10 mg of Saxagliptin and Dapagliflozin (marketed formulation) sample into a 10mL clean dry volumetric flask add about 7mL of Diluent and

sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Limit of Detection: Accurately weigh and transfer 10 mg of Saxagliptin working standard into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Limit of Quantification: Accurately weigh and transfer 10 mg of Saxagliptin working standard into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

Limit of Detection: (for Dapagliflozin) accurately weigh and transfer 10mg of Dapagliflozin working standard into a

# 3. Results and Discussion

100ml clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

# Limit of Quantification: (for Dapagliflozin)

Accurately weigh and transfer 10mg of Dapagliflozin working standard into a 100mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent.

#### **Robustness:**

As part of the Robustness, deliberate change in the Flow rate, Mobile Phase composition, Temperature Variation was made to evaluate the impact on the method.

Table 1: Results of system suitability parameters for Saxagliptin and Dapagliflozin

S.No	Name	Retention time(min)	Area (μV sec)	Height (μV)	USP resolution	USP tailing	USP plate count
1	Saxagliptin	2.5	124505	213642		1.2	4673.4
2	Dapagliflozin	3.9	1308495	154566	6 0	1.3	6090.3

Table 2: Results of method precession for Saxagliptin

Tuble 2. Ites and of mother procession for sumaging an					
Injection	Area				
Injection-1	1302729				
Injection-2	1302947				
Injection-3	1303236				
Injection-4	1303977				
Injection-5	1309759				
Average	1304529.8				
Standard Deviation	2961.1				
%RSD	0.2				

**Table 3:** Results of method precession for Dapagliflozin

Tubic Control and modified procession for BulgariteEm				
Injection	Area			
Injection-1	123149			
Injection-2	123766			
Injection-3	124271			
Injection-4	124691			
Injection-5	124956			
Average	124162.7			
Standard Deviation	725.6			
%RSD	0.6			

**Table 4:** Results of Intermediate precision for Saxagliptin

Injection	Area
Injection-1	1300148
Injection-2	1304520
Injection-3	1305937
Injection-4	1306476
Injection-5	130871
Average	1305070.2
Standard Deviation	3061.8
%RSD	0.2

Table 5: Results of Intermediate precision for Dapagliflozin

Injection	Area
Injection-1	122487
Injection-2	122626

Thirupathi Krishna et al, Int. J. Med. Pharm. Res., 2020, 8(1): 09-13

Injection-3	122632
Injection-4	122702
Injection-5	122962
Average	122681.8
Standard Deviation	174.8
%RSD	0.1

Table-6 Accuracy (recovery) data for Saxagliptin

% Concentration	Area	Amount Added	Amount		
(at specification Level)		(mg)	Found (mg)	% Recovery	Mean Recovery
50%	656659.5	5.0	5.036	100.7%	
100%	1304258	10.0	10.003	100.0%	99.84%
150%	1854608	14.4	14.224	98.780%	

Table-7 Accuracy (recovery) data for Dapagliflozin

%Concentration		Amount	Amount Found	% Recovery	Mean Recovery
(at specification Level)	Area	Added (mg)	(mg)		
50%	65800	5.3	5.34	100.8%	
100%	124353	10	10.10	100.01%	
150%	177940	14.2	14.45	99.68%	100.51%

Table-8 Area of different concentration of Saxagliptin

S.No.	Linearity Level	Concentration	Area
1	I	100ppm	668934
2	II	200ppm	956781
3	III	300ppm	1313873
4	IV	400ppm	1563458
5	V	500ppm	1867084
	0.999		

Table-9: Area of different concentration of Dapagliflozin

S.No	Linearity Level	Concentration	Area
1	I	1ppm	66510
2	II	2ppm	94701
3	III	3ppm	124802
4	IV	4ppm	152731
5	V	5ppm	179732
Correlat	ion Coefficient	0.999	




Figure 2 calibration graph for Saxagliptin at 225 nm

20000 f

18000 f

180

Figure 3 calibration graph for Dapagliflozin at 225 nm

Table-10 Results of LOD

Drug name	Baseline noise(µV)	Signal obtained (µV)	S/N ratio
Saxagliptin	52	152	2.9
Dapagliflozin	52	156	3

#### Table no-11 Results of LOO

Drug name	Baseline noise(µV)	Signal obtained (μV)	S/N ratio
Saxagliptin	52	522	10.03
Dapagliflozin	52	524	10.1

#### 4. Conclusion

High performance liquid chromatography is at present one of the most sophisticated tool of the analysis. The estimation of Saxagliptin and Dapagliflozin was done by RP-HPLC. The Phosphate buffer was p<sup>H</sup> 3.0 and the mobile phase was optimized with consists of Methanol: Phosphate buffer mixed in the ratio of 70:30 % v/ v. Inertsil  $C_{18}$  column C18 (4.6 x 150mm,  $5 \square m$ ) or equivalent chemically bonded to porous silica particles was used as stationary phase. The detection was carried out using UV detector at 260 nm. The solutions were chromatographed at a constant flow rate of 0.8 ml/min. the linearity range of Saxagliptin and Dapagliflozin were found to be from 100-500mg/ml of Saxagliptin and 1-5mg/ml of Dapagliflozin. Linear regression coefficient was not more than 0.999. The values of % RSD are less than 2% indicating accuracy and precision of the method. The percentage recovery varies from 98-102% of Saxagliptin and Dapagliflozin. LOD and LOQ were found to be within limit. The results obtained on the validation parameters met ICH and USP requirements .it inferred the method found to be simple, accurate, precise and linear. The method was found to be having suitable application in routine laboratory analysis with high degree of accuracy and precision.

#### 5. References

- [1] Campbell DB, Lavielle R, Nathan C. The Mode of Action and Clinical Pharmacology of Gliclazide: A Review. Diab Res Clin Prac.1991; 14:S21-S36.
- [2] Herman G, Bergman A, Liu F, Stevens C, Wang A, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan A, Lasseter K, Dilzer S, Blum R, Wagner J. Pharmacokinetics And Pharmacodynamic Effects of the Oral DPP-4 Inhibitor Sitagliptin in Middle-Aged Obese Subjects. J.Clin.Pharmacol.2006; 46 (8): 876–886.
- [3] Florentin T, Monica A .Specificity of an Analytical Hplc Assay Method of Metformin Hydrochloride. Revue Roumaine De Chimie.2007; 52(6):603–609.
- [4] Georgita C, Albu F, David V, Medvedovici A.Simultaneous Assay Of Metformin And Glibenclamide In Human Plasma Based On Extraction-Less Sample Preparation Procedure And LC /(APCI)MS. J.Chromatogr. B.2007; 854(1-2):211-218.
- [5] Ramakrishna Nirogi, Vishwottam Kandikere, Koteshwara Mudigonda, Prashanth Komarneni, Raghupathi Al Eti, Rajeshkumar Boggavarapu. Sensitive Liquid Chromatography Tandem Mass Spectrometry Method For The Quantification Of Sitagliptin, A DPP-4 Inhibitor, In Human Plasma Using Liquid–Liquid Extraction. Biomed. Chromatogr.2008; 22(2): 214–222.

[6] Patil S.S., Bonde C. Development and Validation of Analytical Method for Simultaneous Estimation of Glibenclamide And Metformin Hcl In Bulk And Tablets Using UV Visible Spectroscopy, Int. J. Chemtec. Res. 2009, 1(4): 905-909.